Capricor Shares Gain Ahead of Key Duchenne Data and Financial Update
Capricor Therapeutics shares advanced 7.6% as the company prepares to release quarterly results and full Phase 3 data for its Duchenne muscular dystrophy drug deramiocel on March 12.
Earnings
